Generic Atzumi Availability
Last updated on Jul 9, 2025.
Atzumi is a brand name of dihydroergotamine, approved by the FDA in the following formulation(s):
ATZUMI (dihydroergotamine mesylate - powder;nasal)
-
Manufacturer: SATSUMA PHARMS
Approval date: April 30, 2025
Strength(s): EQ 5.2MG BASE [RLD]
Is there a generic version of Atzumi available?
No. There is currently no therapeutically equivalent version of Atzumi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atzumi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions, devices, and methods for treating or preventing headaches
Patent 10,758,532
Issued: September 1, 2020
Inventor(s): Kollins; John et al.
Assignee(s): Satsuma Pharmaceuticals, Inc. (South San Francisco, CA)Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.
Patent expiration dates:
- December 11, 2039✓
- December 11, 2039
-
Pharmaceutical compositions
Patent 10,792,253
Issued: October 6, 2020
Inventor(s): Haruta; Shunji
Assignee(s): Shin Nippon Biomedical Laboratories, Ltd. (Kagoshima, JP)Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.
Patent expiration dates:
- August 4, 2037✓
- August 4, 2037
-
Intranasal delivery devices
Patent 11,744,967
Issued: September 5, 2023
Inventor(s): Haruta; Shunji
Assignee(s): SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (Kagoshima, JP)The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.
Patent expiration dates:
- October 12, 2041✓
- October 12, 2041
-
Pharmaceutical compositions
Patent 11,872,314
Issued: January 16, 2024
Inventor(s): Haruta; Shunji
Assignee(s): Shin Nippon Biomedical Laboratories, Ltd. (Kagoshima, JP)Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.
Patent expiration dates:
- August 4, 2037✓
- August 4, 2037
-
Intranasal delivery devices
Patent 12,102,754
Issued: October 1, 2024
Inventor(s): Haruta; Shunji
Assignee(s): SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (Kagoshima, JP)The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.
Patent expiration dates:
- October 12, 2041✓
- October 12, 2041
-
Compositions, devices, and methods for treating or preventing headaches
Patent 12,263,162
Issued: April 1, 2025
Inventor(s): Kollins; John et al.
Assignee(s): SATSUMA PHARMACEUTICALS, INC. (South San Francisco, CA)Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.
Patent expiration dates:
- December 11, 2039✓
- December 11, 2039
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 30, 2028 - NEW PRODUCT
More about Atzumi (dihydroergotamine)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
Patient resources
Other brands
Migranal, Trudhesa, Brekiya, D.H.E. 45
Professional resources
Other brands
Migranal, Trudhesa, Brekiya, D.H.E. 45
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.